Isomorphic Labs said on 17 November that it had raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital, following an earlier $2.1 billion Series B. The London-based company designs drug candidates using AI simulation models.
Isomorphic Labs described the round as oversubscribed. It said Andreessen Horowitz and other new investors joined, alongside further investment from Alphabet and participation by existing backers Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. An earlier AI Affairs report described funding talks at a valuation of at least $40 billion.
The company says its IsoDDE drug design engine combines simulation models for work across multiple therapeutic areas and drug types. It reported positive preclinical results in internal oncology and immunology programmes and work with partners. Isomorphic Labs said the proceeds would support further model development, its drug candidate pipeline and infrastructure for clinical development.